Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Pharming Group N-V stock

Learn how to easily invest in Pharming Group N-V stock.

Pharming Group N.V. is a biotechnology business based in the US. Pharming Group N-V shares (PHAR) are listed on the NASDAQ and all prices are listed in US Dollars. Pharming Group N-V employs 262 staff.

How to buy shares in Pharming Group N-V

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – PHAR – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Pharming Group N-V stock price (NASDAQ: PHAR)

Use our graph to track the performance of PHAR stocks over time.

Pharming Group N-V shares at a glance

Information last updated 2021-10-10.
52-week range$0.00 - $0.00
50-day moving average $0.00
Wall St. target priceN/A
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy Pharming Group N-V shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Pharming Group N-V stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Pharming Group N-V financials

Gross profit TTM $0
Return on assets TTM 0%
Return on equity TTM 0%
Profit margin 0%
Book value N/A
Market capitalisation $0

TTM: trailing 12 months

Shorting Pharming Group N-V shares

There are currently 226 Pharming Group N-V shares held short by investors – that's known as Pharming Group N-V's "short interest". This figure is 73.7% down from 859 last month.

There are a few different ways that this level of interest in shorting Pharming Group N-V shares can be evaluated.

Pharming Group N-V's "short interest ratio" (SIR)

Pharming Group N-V's "short interest ratio" (SIR) is the quantity of Pharming Group N-V shares currently shorted divided by the average quantity of Pharming Group N-V shares traded daily (recently around inf billion). Pharming Group N-V's SIR currently stands at 0. In other words for every 100,000 Pharming Group N-V shares traded daily on the market, roughly 0 shares are currently held short.

To gain some more context, you can compare Pharming Group N-V's short interest ratio against those of similar companies.

However Pharming Group N-V's short interest can also be evaluated against the total number of Pharming Group N-V shares, or, against the total number of tradable Pharming Group N-V shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Pharming Group N-V's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Pharming Group N-V shares in existence, roughly 0 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Pharming Group N-V shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Pharming Group N-V.

Find out more about how you can short Pharming Group N-V stock.

Pharming Group N-V share dividends

We're not expecting Pharming Group N-V to pay a dividend over the next 12 months.

Pharming Group N-V overview

Pharming Group N. V. , a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre- eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.

Frequently asked questions

How many people work for Pharming Group N-V?
Latest data suggests 262 work at Pharming Group N-V.
When does the fiscal year end for Pharming Group N-V?
Pharming Group N-V's fiscal year ends in December.
What is Pharming Group N-V's ISIN number?
Pharming Group N-V's international securities identification number is: US71716E1055
What is Pharming Group N-V's CUSIP number?
Pharming Group N-V's Committee on Uniform Securities Identification Procedures number is: 71713J107

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site